SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is trending as gold prices reach record highs, fueled by economic uncertainty, trade tensions, and speculation around potential Federal Reserve rate cuts. The community is debating whether this rally signals a larger economic shift or if it's a bubble poised to burst, with some pointing to a potential currency reset. Bullish sentiment prevails as many anticipate further gains, while bears remain cautious, citing overbought conditions.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as community sentiment turns bearish despite a potential $70 price target from HSBC, with traders citing frustration over the stock's underperformance relative to competitors like Eli Lilly. Recent news, including cost-cutting measures and a $4.7B acquisition of Akero Therapeutics to diversify beyond GLP-1 drugs, is fueling debate about management's strategic direction and the company's growth prospects. Some investors express concerns about competition and pricing pressures, while others maintain a bullish long-term outlook, anticipating positive catalysts from FDA approvals and Alzheimer's drug trials.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly ($LLY) is trending due to positive Phase 3 trial results for its oral GLP-1 pill, orforglipron, showing significant A1C reductions and weight loss. Community discussions revolve around its potential to outperform competitors and become a new standard of care for type 2 diabetes, while some traders are reacting to news about potential price negotiations influenced by the Trump administration which creates uncertainty.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

The WAGMI community remains highly engaged, emphasizing conviction and a long-term outlook with the phrase "We're All Gonna Make It." Discussions revolve around accumulating more $WAGMI, viewing dips as opportunities, and highlighting the strength and bonding of the community. Bullish sentiment is high, with community members focused on long-term growth.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors digest the implications of a recent debt financing deal and its expansion into AI/HPC infrastructure, with community discussion focused on the absence of share dilution and Google's backing. Despite an initial market selloff reacting to the debt headline, the community anticipates a rebound as the market recognizes the company's growth potential and shift towards clean AI data centers. Bullish sentiment is fueled by rising price targets and anticipation of a short squeeze, although some remain cautious due to broader market concerns.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxis Precision Medicines ($PRAX) is trending due to positive Phase 3 trial results for its essential tremor treatment, driving significant price movement and analyst upgrades. The community is actively discussing the possibility of a stock offering and its potential impact on the stock's valuation, as well as debate between bullish and bearish sentiments surrounding the news. Some traders are also highlighting the stock's high institutional ownership and potential for a short squeeze.

Interactive Brokers Group, Inc. is an investment holding company, which engages in broker or dealer and proprietary trading businesses. It offers custody and service accounts for hedge and mutual funds, exchange-traded funds, registered investment advisors, proprietary trading groups, introducing brokers, and individual investors. The company was founded by Thomas Pechy Peterffy in 1977 and is headquartered in Greenwich, CT.

Interactive Brokers Group Inc - Ordinary Shares - Class A

Interactive Brokers Group Inc 

Interactive Brokers is trending after reporting strong earnings, leading to increased discussion about its valuation and potential. While some investors are taking profits, the community highlights the company's solid financials and expanding business. There's also debate about whether IBKR or competitors like Robinhood are better positioned for future growth, with some anticipating further upward momentum for IBKR.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge, driven by a potential short squeeze in London and expectations of future rate cuts. The community is actively discussing the possibility of silver reaching new all-time highs, with some speculating about a run to $100/oz. Regional bank instability and a potential flight to safety are also fueling the conversation around silver's appeal as a safe-haven asset.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

ATAI Life Sciences N.V.

ATAI Life Sciences is trending due to a combination of factors: recent FDA breakthrough therapy designation for its depression drug and positive phase 2b trial results are boosting investor confidence. However, news of a proposed public offering is sparking concerns about potential share dilution, leading to active discussions within the community on whether to buy or sell.

Gitlab, Inc. provides code hosting and collaboration platform services. It offers continuous integration, source code management, out-of-the-box pipelines, agile development, and value stream management. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in Dover, DE.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is trending due to reported takeover interest from Datadog, with a potential bid over $60 per share, sparking speculation of a bidding war with Google. The community is actively discussing the possibility of a deal and its potential valuation, with some suggesting figures well above the rumored offer price. Some traders are cautious, citing past false rumors and potential for quick gains to be given back.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates

MaxCyte (MXCT) delivered earnings and revenue surprises of -20.00% and -14.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)

Glancy Prongay & Murray LLP (GPM) announces its investigation of MaxCyte, Inc. (NASDAQ: MXCT) concerning the Company and its directors and officers possible violations of state laws. If you own...

MaxCyte Director Executes Stock Options and Sells

MaxCyte (MXCT) has released an update. MaxCyte Inc., a leader in cell-engineering, has reported that their Non-Executive Director, John Johnston, h...

MaxCyte Announces Broker Name Change Post-Merger

MaxCyte (MXCT) has released an update. MaxCyte Inc., a leader in cell-engineering platform technologies, has announced a change of its Nominated Ad...

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

Be Biopharma to use MaxCyte's Flow Electroporation technology and ExPERT platform within its Engineered B Cell Medicines programsROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc...

Commit To Buy MaxCyte At $2.50, Earn 6.7% Annualized Using Options

Investors considering a purchase of MaxCyte Inc (MXCT) shares, but cautious about paying the going market price of 4.26/share, might benefit from considering selling puts among the alternative...

MaxCyte price target lowered by $2 at BTIG, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

MaxCyte affirms FY24 guidance

MaxCyte reports Q4 EPS (5c), consensus (7c)

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

MaxCyte Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$1.77
Prev Close	$1.83
Open	$1.82
Dividend Yield	0.00%
50-Day Moving Average	$1.50
Beta	1.49
Avg. Volume	779,901.86
PE Ratio	-4.32

52-Week High	$5.20
52-Week Low	$1.26
Market Capitalization	$195.09M
EPS (Annual)	-$0.3916
Price to Book	1.02
Revenue Per Employee	$338,833.33
Enterprise Value/EBITDA	N/A

MXCT
MaxCyte Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MXCT News

MXCTMaxCyte Inc